Justyna Ceryn, Aleksandra Lesiak, Dorota Sobolewska-Sztychny, Marcin Noweta, Magdalena Ciążyńska, Joanna Narbutt
{"title":"Actinic keratosis: comprehensive review of current treatments and emerging therapeutic innovations.","authors":"Justyna Ceryn, Aleksandra Lesiak, Dorota Sobolewska-Sztychny, Marcin Noweta, Magdalena Ciążyńska, Joanna Narbutt","doi":"10.5114/ada.2024.147331","DOIUrl":null,"url":null,"abstract":"<p><p>Actinic keratosis (AK) is a prevalent benign intraepidermal dysplasia, classified as squamous cell carcinoma <i>in situ</i> (SCC <i>in situ</i>). Chronic ultraviolet (UV) light exposure is the primary etiological factor for AK, which predominantly manifests in sun-exposed areas. Management of AK emphasizes primary prevention through education, sun protection, and vigilant patient monitoring. Therapeutic strategies for AK are categorized into lesion-directed and field-directed approaches, encompassing topical treatments (imiquimod, 5-fluorouracil, diclofenac) and physical modalities (cryotherapy, photodynamic therapy, chemical peels, laser therapy, electrocoagulation, curettage). This comprehensive review discusses the current treatments and explores novel therapeutic options for AK.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"221-231"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262025/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2024.147331","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Actinic keratosis (AK) is a prevalent benign intraepidermal dysplasia, classified as squamous cell carcinoma in situ (SCC in situ). Chronic ultraviolet (UV) light exposure is the primary etiological factor for AK, which predominantly manifests in sun-exposed areas. Management of AK emphasizes primary prevention through education, sun protection, and vigilant patient monitoring. Therapeutic strategies for AK are categorized into lesion-directed and field-directed approaches, encompassing topical treatments (imiquimod, 5-fluorouracil, diclofenac) and physical modalities (cryotherapy, photodynamic therapy, chemical peels, laser therapy, electrocoagulation, curettage). This comprehensive review discusses the current treatments and explores novel therapeutic options for AK.
光化性角化病（AK）是一种常见的良性表皮内发育不良，属于鳞状细胞原位癌（SCC in situ）。慢性紫外线（UV）照射是AK的主要病因，主要表现在阳光照射的地区。AK的管理强调通过教育、防晒和警惕的患者监测进行初级预防。AK的治疗策略分为病变定向和场定向方法，包括局部治疗（咪喹莫德、5-氟尿嘧啶、双氯芬酸）和物理治疗（冷冻治疗、光动力治疗、化学换肤、激光治疗、电凝、刮除）。这篇综述讨论了目前治疗AK的方法，并探索了新的治疗选择。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
